Why the Bull Case for Boston Scientific Stock Is Robotic Assisted Procedures Growth

Boston Scientific's stock gains from growing robotic-assisted procedures not through owning robots, but through supplying essential consumables and enabling systems.

Boston Scientific's stock gains from growing robotic-assisted procedures not through owning robots, but through supplying essential consumables and enabling systems.

In early 2026, Stryker launched Mako RPS, a handheld version of its robotic knee surgery system, designed to reach ambulatory surgery centers (ASCs),...

RTX's military robotics programs are already in development—not future promises, but contracts with deployment timelines.

Pentagon planning to buy up to 1 million drones drives AeroVironment's record revenue growth and expands its multi-year backlog.

UiPath's path to profitability and accelerating growth positions it as a gatekeeper for enterprise automation at the moment when processes transition from rules-based to AI-driven.

John Deere's dealer network and data platform create structural advantages that make autonomous farming robots a natural next revenue stream for the company.

Teradyne's robotics business is recovering after 2025 challenges, backed by a cobot market expected to quadruple by 2033.

Zebra's exit from robotics hardware paradoxically strengthens its bull case: machine vision and tracking demand is accelerating, and Zebra now sells the software layer that powers automation.

Rockwell Automation's growth hinges on US manufacturing reshoring and the expanding demand for AI-driven factory automation systems.

ABB's bull case is electrification and automation dominance, not robotics—which it is selling to SoftBank.